External site

By following this link, you are leaving Medically and entering a website that is not owned or controlled by Roche. Roche does not take any responsibility for access to or use of this website, nor for any content therein.

Leave site
Home Oncology NACLC 2025
Roche and Genentech at

NACLC 2025

December 05 - December 07
Chicago, USA
naclc-iaslc.org
Add to calendar
Share feedback
Share page
-
Medical Materials
Agenda
Coming soon
10:00 PM
Duration 90mins Chicago, USA
Patient-reported outcomes (PROs) from IMforte: A Phase 3 study of first-line maintenance treatment with lurbinectedin + atezolizumab versus atezolizumab in patients with extensive-stage small cell lung cancer (ES-SCLC)
Roy S. Herbst, Luis Paz-Ares, Hossein Borghaei, Stephen V. Liu, Solange Peters, Muhammet Bekir Hacıoğlu, Atike Gokcen Demiray, Adam Płużański, Giannis Mountzios, Athanasios Kotsakis, Stefan Hammerschmidt, Gabriella Gálffy, Eleni Karapanagiotou, Siobhan Connor-Ahmad, Carla Mamolo, Ya-Chen Lin, Jonathon Gable, Debasis Chakrabarti, George Cai, Martin Reck
Oncology | Small Cell Lung Cancer

You have successfully signed up for this alert. You will be notified when it is available.

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar

This website is intended for healthcare professionals outside the United Kingdom (UK) and Australia. Registration status and prescribing information of medicinal products may differ between countries. Please refer to local product information for any medicinal products mentioned on this website.